TheEdgeResearch
Home / Stocks / LAB

Standard BioTools Inc. (LAB)

NASDAQ Healthcare Medical - Equipment & Services
$0.78 ▼ -0.95%
Market Cap
$305.3M
Sector
Healthcare
Industry
Medical - Equipment & Services
Beta
1.42
52-Wk Range
0.7-1.72
CEO
Michael Egholm
Country
US
Currency
USD

Standard BioTools Inc. operates in the Medical - Equipment & Services industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $0.78, down 0.95% on the session, giving a market capitalisation of $305.3M. On trailing twelve-month figures it carries a trailing P/E of -3.38, a net margin of -103.3%. Its beta of 1.42 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-3.38
Price / Sales
3.61
Price / Book
0.56
EV / EBITDA
-0.69
Gross margin
49.1%
Operating margin
-94.8%
Net margin
-103.3%
Return on equity
Debt / equity
0.05
Current ratio
9.10
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
387
IPO date
2011-02-10
Headquarters
Boston, MA, US
About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Comparable companies

Standard BioTools Inc. is most often compared with the following Healthcare names:

ADCTAVNSBVSCBLLCGEMCTKBKIDSSYTMCIVREX
More research on LAB
LAB technical analysis LAB TheEdge Score Compare against peers
Open full interactive analysis & DCF →